Growth private equity fund research profile
Motilal Oswal India Business Excellence Fund IV is a closed India-focused growth-equity vehicle backing mid-market companies. Public records directly identify Pathkind Diagnostics, Simpolo Vitrified, Niva Bupa Health Insurance and VVDN Technologies in IBEF IV-related transactions, giving demand-side advisers a vehicle-specific view separate from the manager’s Fund V and real-estate or credit strategies.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Motilal Oswal India Business Excellence Fund IV uses a growth private equity; mid-market indian businesses approach across Consumer, financial services, life sciences, manufacturing.
Current evidence
Motilal Oswal’s current private-equity page continues to identify IBEF IV as a 2022 US$550 million fund with 13 investments, while the group’s 2024–25 annual report and current private-equity platform provide vehicle context. Issuer and regulatory records preserve the attributable IBEF IV positions in Pathkind, Simpolo, Niva Bupa and VVDN.
Strategy
Growth private equity; mid-market Indian businesses
Sector focus
Consumer, financial services, life sciences, manufacturing
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
Motilal Oswal’s current private-equity page continues to identify IBEF IV as a 2022 US$550 million fund with 13 investments, while the group’s 2024–25 annual report and current private-equity platform provide vehicle context. Issuer and regulatory records preserve the attributable IBEF IV positions in Pathkind, Simpolo, Niva Bupa and VVDN.
Investor questions
Motilal Oswal India Business Excellence Fund IV is covered in Rupeia's private equity research universe. The current public record describes the strategy as Growth private equity; mid-market Indian businesses, with a sector focus of Consumer, financial services, life sciences, manufacturing. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to Motilal Oswal India Business Excellence Fund IV in the reviewed public sources: Pathkind Diagnostics; Simpolo Vitrified; Niva Bupa Health Insurance; VVDN Technologies. It does not represent a complete current portfolio unless the manager has published one.
Motilal Oswal reports 13 IBEF IV investments and a US$550 million vehicle size. Public transaction and issuer records document IBEF IV investments in Pathkind Diagnostics, Simpolo Vitrified, Niva Bupa and VVDN; vehicle-level net IRR, DPI and TVPI are not publicly disclosed. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: US$550 million fund size on Motilal Oswal’s official funds page; IFC separately describes an approximately US$588 million aggregate commitment target for the master/GIFT structure.. Public terms or access information: Category II AIF investing in equity, equity-linked, debt, mezzanine and other instruments of Indian or India-related mid-market companies. Complete fees, carry, hurdle, tenor and reserve terms are not disclosed.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Vishal Tulsyan (Managing Director); Raamdeo Agrawal (Founder and IC Member); Rohit Mantri (Managing Director and Co-Head, Private Equity); Vijay Dhanuka (Managing Director and Co-Head, Private Equity). Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: The complete IBEF IV allocation schedule, current ownership percentages, fees, carry, reserve policy and audited net returns are not publicly disclosed. The four names are retained because public fund, CCI, issuer and transaction records identify IBEF IV or its direct investment in the company; the record does not import unrelated Motilal Oswal funds..
2025-04-30: Motilal Oswal’s current private-equity page continues to identify IBEF IV as a 2022 US$550 million fund with 13 investments, while the group’s 2024–25 annual report and current private-equity platform provide vehicle context. Issuer and regulatory records preserve the attributable IBEF IV positions in Pathkind, Simpolo, Niva Bupa and VVDN.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.